Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.36 |
| ▸ | BCL9 | O00512 | 2/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | CDK1 | P06493 | 3/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26881272 | 1.00 | CDK2 (0.40) | CDK2PIK3CBBCL9CTNNB1PIK3CA | |
| SCHEMBL30741981 | 1.00 | CDK2 (0.40) | CDK2PIK3CBBCL9CTNNB1PIK3CA | |
| SCHEMBL27129095 | 1.00 | CDK2 (0.40) | CDK2PIK3CBBCL9CTNNB1PIK3CA | |
| SCHEMBL27135536 | 0.85 | CYP1A1 (0.42) | CDK2PIK3CA | |
| SCHEMBL26881276 | 0.85 | CYP1A1 (0.42) | CDK2PIK3CA | |
| SCHEMBL24913011 | 0.83 | ALDH1A1 (0.46) | CDK2PIK3CBPIK3CACSNK2A2CSNK2B | |
| SCHEMBL26880870 | 0.83 | ALDH1A1 (0.46) | CDK2PIK3CBPIK3CACSNK2A2CSNK2B | |
| SCHEMBL26882186 | 0.82 | PIK3CA (0.39) | CDK2PIK3CBPIK3CA | |
| SCHEMBL26882190 | 0.82 | PIK3CA (0.39) | CDK2PIK3CBPIK3CA | |
| SCHEMBL30584385 | 0.82 | ALDH1A1 (0.45) | CDK2PIK3CBPIK3CACSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | CDK2 296/4885PIK3CB 16/4885BCL9 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.